Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095057
Filing Date
2024-08-12
Accepted
2024-08-12 07:02:31
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lxeo-20240630.htm   iXBRL 10-Q 2303349
2 EX-10.1 lxeo-ex10_1.htm EX-10.1 526399
3 EX-10.2 lxeo-ex10_2.htm EX-10.2 116659
4 EX-10.3 lxeo-ex10_3.htm EX-10.3 373482
5 EX-31.1 lxeo-ex31_1.htm EX-31.1 12122
6 EX-32.1 lxeo-ex32_1.htm EX-32.1 6787
  Complete submission text file 0000950170-24-095057.txt   9371615

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20240630.xsd EX-101.SCH 1252222
65 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20240630_htm.xml XML 1178340
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41855 | Film No.: 241194702
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)